A biotech startup formed by Atlas Venture is collaborating with Biogen Idec to develop a treatment for inherited forms of Ataxia a degenerative neurological condition that leads to physical disabilities, according to a company statement. They include the loss of coordination of hands, fingers, arms, legs but it can also cause a curvature of the spine and heart problems such as arrhythmias. Ataxion has raised $17 million in a Series A round to develop treatments for inherited versions of the disease from Atlas Venture and Biogen. Friedreichs ataxia is the most common version of the orphan disease, which affects under 200,000 people. The condition, which tends to show symptoms in adolescence, has no known cure and has been the subject of increasing attention from the life sciences industry and research institutions. It reflects a broader life sciences industry trend of developing treatments for orphan diseases because theres a higher barrier to entry and it allows companies to keep exclusivity for longer periods of time than conditions with larger patient populations. Atlas Venture formed Ataxion last year when it licensed the technology from Danish biotech company Aniona, since renamed Saniona. The treatments under development focused on using potassium channel activators to … Continue reading →

Hlio Diamantino, 33 years old, was a young man who cherished life and, despite the difficulties, he always could count on the love of his family. This was until the day he was stricken by an illness while completing compulsory military service between 2001 and 2002. At present, he is a young man whose future is passing him by. He has lost most of his motor skills and represents a concern for his mother who can no longer afford the costs of an illness which was caused by the State. In 2011, @Verdade published a story about Hlio, but the State remained deaf and mute concerning the case. At the age of 18, Hlio Diamantino enrolled in the armed forces in order fulfill his patriotic duty and in no way did he think that this decision would spoil his future. "I was in 11th grade and I dreamed of continuing with my studies, but I could not ignore my duties as a citizen of this country." A year later, in 2000, Hlio was summoned by the Centre for Recruitment, Mobilization and Propaganda in Maputo for a medical inspection. He passed the medical exam and was added to a group of … Continue reading →

"A Decade Later, Genetic Map Yields Few New Cures," said a New York Times headline in June 2010. It declared the failure of the $3 billion Human Genome Project and claimed that medicine had seen none of the benefits that President Bill Clinton had promised in announcing the first draft of the human-genome sequence in 2000. According to the article, geneticists were "almost back to square one in knowing where to look for the roots of common disease." The New York Times judged the project too soon. The cost of sequencing a human genome had fallen from about $100 million in 2001 to $30,000 when the article was written; today, it can be done for nearly $1,000. And the promise is coming true. Hardly a week passes without the announcement of a major scientific breakthrough in genomics. The March 6 edition of The New England Journal of Medicine detailed how human cells can be genetically engineered to make them resistant to the virus that causes AIDS. A week earlier, the journal published a finding that analyzing fetal DNA in a pregnant woman's blood was a more accurate -- and less intrusive -- way of screening for Down syndrome and other … Continue reading →

Best Local Orthopedic Specialist Bronx Looking for an Orthopedic Specialist? Watch Informative Medical Advice Segments, Doctor Reviews Doctor Ratings in Your Search to Find the BestLocal Physici... By: BestLocal Bronx … Continue reading →

Cpl Hanes to travel to China for stem-cell therapy A year after returning home a combat wounded veteran, Matthew Hanes is traveling to China for stem-cell therapy. By: York Dispatch … Continue reading →

Henderson, Nevada (PRWEB) March 18, 2014 According to Dr. Srinubabu Gedela, the Managing Director of OMICS Publishing Group , the main aim of the Cell Science-2014 is to broadening the scope of the research in this field. The OMICS Group Conferences 4th world congress on Cell Science & Stem Cell Research deliberates on the broader areas of Evolution of cancer, Tumorogenesis, Recombinant DNA technology, Cancer cell development and signaling pathway, Genetic engineering and Gene therapy, Tumor suppressor genes, Tissue Engineering, Stem cell treatment, Bioinformatics and Computational biology, Bio Ethics and Patent Rights. Reputed speakers at the Cell Science-2014, an international medical conference 2014, including Stewart Sell of University of Albany, USA, Sudhakar Akul Yakkanti, SRI International, USA, Jimmy Thomas Efrid, Brody School of Medicine, USA and Diana Anderson, University of Bradford, UK are going to share their experiences in this field. OMICS Group International, an open access publisher that publishes 300 online, peer reviewed science journals in the fields of Clinical, Medical, Engineering and technological, Pharmaceutical and Management fields also organizes more than 100 international science conferences and events across the globe. With the help of more than 150 scientific associations with the like-minded organization, OMICS Group is contributing for … Continue reading →